Results 131 to 140 of about 51,436 (262)

Halogen-dependent electronic regulation of reactivity and acetylcholinesterase recognition in halomethyl acetates: a predictive DFT-docking framework. [PDF]

open access: yesJ Comput Aided Mol Des
Dahham Abed Abed M   +4 more
europepmc   +1 more source

Acetylcholinesterase

open access: yesJournal of Biological Chemistry, 1973
Basil D. Roufogalis, Virginia M. Wickson
openaire   +1 more source

Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi‐Stage Computational Analysis

open access: yesJournal of Computational Chemistry, Volume 47, Issue 21, August 5, 2026.
How can a single molecule address the complex symptoms of Rett syndrome? This computational study maps the multi‐target mechanism of trofinetide, revealing diverse modes of binding across five key receptors: GAT1, GABAA, CHRM1, AMPA, and GSK3β. From deep orthosteric anchoring to dynamic surface interactions, these structural insights provide a rational
Luis Felipe Hernández‐Ayala   +2 more
wiley   +1 more source

Acetylcholinesterase

open access: yesMolecular Pharmacology, 1972
Gabor Kato, Estrella Tan, James Yung
openaire   +2 more sources

Advancements in Enzymatic Biofuel Cells for Wearable Electrochemical Biosensors: Powering Point‐of‐Care Health Monitoring

open access: yesAdvanced Sensor Research, Volume 5, Issue 8, August 2026.
Advances in enzymatic biofuel cells are highlighted through innovative electrode architectures, enzyme immobilization strategies, and hybrid integration with triboelectric, piezoelectric, and thermoelectric energy harvesters. These emerging approaches improve power output, operational stability, and biocompatibility, advancing self‐powered wearable and
Rashid Khan   +3 more
wiley   +1 more source

<i>Sparassis crispa</i> and a Bioactive Compound Therein, Ergosterol, Were Effective in Preventing Acetylcholinesterase Inhibition In Vitro and In Vivo. [PDF]

open access: yesFood Sci Nutr
Park CK   +13 more
europepmc   +1 more source

Plasma P‐tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION This analysis of the phase 3 TRAILBLAZER‐ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p‐tau217) level can reliably monitor treatment‐related amyloid clearance (TRAC) after donanemab treatment in early symptomatic Alzheimer's disease (AD).
Emily C. Collins   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy